CAMERON HOWELL: Open Payments
NPI 1033876628 · WILMINGTON, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$666 in 42 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $1,315 · 2025 $666
Food & beverage: $666
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $144 |
| Novo Nordisk Inc | 7 | $136 |
| AstraZeneca Pharmaceuticals LP | 3 | $49 |
| GlaxoSmithKline, LLC. | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $35 |
| Exact Sciences Corporation | 2 | $31 |
| Corcept Therapeutics | 2 | $30 |
| SCILEX PHARMACEUTICALS INC. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $22 |
Products named: Ozempic, QULIPTA, UBRELVY, REXULTI, VRAYLAR, Wegovy, XIFAXAN, SHINGRIX.
Industry payments across NC — which companies pay providers there.
